RFL Stock Summary and Trading Ideas (Rafael Holdings Class B | NYSE:RFL)

Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd.

Rafael Holdings Class B trades on the NYSE stock market under the symbol RFL.

As of April 19, 2024, RFL stock price climbed to $1.76 with 26,006 million shares trading.

RFL has a beta of 0.93, meaning it tends to be less sensitive to market movements. RFL has a correlation of 0.07 to the broad based SPY ETF.

RFL has a market cap of $43.27 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, RFL stock traded as high as $66.44 and as low as $1.44.

The top ETF exchange traded funds that RFL belongs to (by Net Assets): VTI, VXF, IWC, DFAS, DFAT.

RFL has underperformed the market in the last year with a return of -7.9%, while the SPY ETF gained +21.2%. In the last 3 month period, RFL fell short of the market, returning +2.3%, while SPY returned +3.0%. However, in the most recent 2 weeks RFL has outperformed the stock market by returning +1.7%, while SPY returned -4.5%.

RFL support price is $1.65 and resistance is $1.77 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RFL stock will trade within this expected range on the day.